Loading company…
Sionna Therapeutics develops small molecule therapies for cystic fibrosis.
Founded in 2019 and based in Waltham, US, Sionna Therapeutics develops small molecule therapies targeting CFTR protein abnormalities in people with cystic fibrosis. It raised USD 182 million in Series C funding in March 2024, led by Patient Square Capital, with participation from RA Capital Management, OrbiMed Advisors, TPG, Atlas Venture, Cystic Fibrosis Foundation, T. Rowe Price, Q Healthcare Holdings, LLC, Viking Global Investors and Perceptive Advisors. In February 2025, it raised USD 190.59 million in an IPO on Nasdaq under ticker SION, selling 10.59 million shares at USD 18 per share.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in